Founded in 2004 by Stéphane Ragusa, Predilife has pioneered the design and development of prediction tests, giving everyone the chance to find out their own risk of developing serious diseases. It combines proven medical techniques with Artificial Intelligence and Big Data.
Predilife is a company at the heart of predictive medicine. Predictive medicine involves anticipating an individual’s future so that action can be taken in time thanks to personalised prevention, either by reducing risk, or by identifying the disease as early as possible. Serious conditions, such as cancer and heart attack, can be better prevented.
Since 2018, Predilife has been listed on Euronext.
« The sooner the better ».
Stéphane Ragusa, CEO of Predilife, is a graduate of the prestigious École Polytechnique engineering school. For several years, he has implemented many innovations in the field of predictive and preventive medicine to enable men and women to anticipate their risk of developing serious diseases, and consequently to take action.
The Predilife Board, comprising Stéphane Ragusa, Élise Tronel, Émilien Gauthier and Marion Renelier, is supported by 5 developers, 8 employees and 8 sales representatives in France and abroad.
Chief Executive Officer
Chief Technology Officer
The history of Predilife
by Stéphane Ragusa
Contract with INSERM for access to their cohorts of data
Contract with BCSC (Breast Cancer Surveillance Consortium) for access to their database on 1,000,000 American women.
First FDA agreement obtained for DenSeeMammo
Riviera study (NCT02997384) sponsored by Gustave Roussy and funded by ARC (Association for Cancer Research), aiming to show the acceptability and feasibility of breast cancer risk consultations in community practice.
Predilife goes public. CE marking for MammoRisk and DenSeeMammo.
The MyPeBS study is launched.
Access to the French and European market.
Deployment of a sales team in France and Europe.
CE marking of risk prediction medical devices for cancers: prostate, colon, lung and for heart attack